On Tuesday, July 28, 2026, three new lawsuits against GLP-1 drug makers were tracked, all filed by patients rather than regulators. Eli Lilly and Novo Nordisk each face claims that could affect how these drugs are marketed and labeled going forward. If you take Mounjaro, Zepbound, Ozempic, or Wegovy, these cases are worth watching, even though none of them change what you can access today. Courts, not agencies, are currently driving the conversation around GLP-1 safety disclosures.
The case against Eli Lilly, Browning v. Eli Lilly and Company, centers on a patient's claim that Mounjaro or Zepbound caused serious harm. Lawsuits like this one typically argue that a drug maker failed to adequately warn patients and doctors about risks that later became apparent. Eli Lilly has not been found liable in this case, and the claim is still working through the court system. If you currently take Mounjaro or Zepbound, this filing does not change your prescription or your access to the medication, though it may add to a growing body of litigation that shapes future labeling.
A second case, Montee v. Novo Nordisk A/S, takes a broader approach by alleging that the company hid serious risks tied to its GLP-1 drugs, rather than pointing to one patient's experience. This kind of claim, if it succeeds, could push regulators or the company itself to revise warning labels or patient materials. The lawsuit does not specify what risks were allegedly concealed beyond what is stated in court filings, so patients should rely on their own prescribing information and their doctor's guidance, rather than the lawsuit itself, for current safety facts. Novo Nordisk has not been found liable, and the case remains in early stages.
The third case, Shugart v. Novo Nordisk A/S, is a separate lawsuit involving Ozempic or Wegovy, and it will not change what you pay for these drugs or whether you can get a prescription filled. Patients sometimes worry that pending litigation might trigger a recall or a sudden change in availability, but that is not how these cases typically work while they remain in court. If you are currently on Ozempic or Wegovy, you can continue your treatment as prescribed unless your doctor tells you otherwise. This case is one to watch for what it might reveal about the company's internal knowledge of risks, not for any immediate effect on your care.
If you take a GLP-1 medication from either company, the most useful step right now is to keep track of official communications from your doctor and from the drug makers themselves, rather than reacting to lawsuit headlines. These cases may take months or years to resolve, and their outcomes could eventually influence warning labels or marketing practices, but they do not change your prescription today. It may help to ask your prescriber directly if new safety information becomes available, and to keep a record of any side effects you experience, so you have documentation regardless of how these lawsuits proceed.
Key details
Eli Lilly faces a lawsuit claiming Mounjaro or Zepbound caused serious harm to a patient.
Patients allege Novo Nordisk hid serious risks tied to its GLP-1 drugs in a new lawsuit.
A separate lawsuit against Novo Nordisk won't change your GLP-1 access or cost.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-07-28